The IN-VIVO Blog will no longer be publishing content.  For the latest health-care industry news, analysis and much more, be sure to visit w...

Here at Deals of the Week, we don’t often take note explicitly of buyouts outside the biopharma sphere. But one well-publicized tech deal ...

Despite a slight slowdown, there's considerable cash already sloshing around the biotech IPO space. There's (still!) plenty more sta...

Noting a flurry of recent commentaries in peer-review journals, our February Science Matters column in START-UP ( link here , free access...

As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of t...

While the largest deal of the week, and certainly the one receiving the most attention, has been Actavis' expansion of its branded p...

Somewhere out there, perhaps, is the end of NovImmune's Series B round. More than a year ago, our friends at START-UP examined the ...

Neither MedImmune, the biologics arm of AstraZeneca, nor the University of California, San Francisco, is a stranger to R&D collabo...